Search

everythinglearnresearchcommunity

for

Search:↓

Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.

Telocytes in silky fowl embryos develop distinct features and connections by the 20th day of incubation.

Immune therapy for cancer can cause rare hair loss but doesn't stop treatment success.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Autoimmune diseases cause the immune system to attack the body, and management varies as some are curable and others are not.

Autoimmune diseases cause the immune system to attack the body, and management varies as some are curable and others are not.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

Proinflammatory fibroblasts and vascular endothelial cells are key in keloid development.

Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.

CD4 T cells need IFN-γ to cause hair loss in alopecia areata.

Targeted immunotherapies may offer better treatment for alopecia areata by controlling inflammation and immune responses.

Patients with certain FoxN1 gene mutations have severe immune issues but normal skin and hair.

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.

CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.

Stem cells help control the immune response to improve wound healing.

Biodegradable scaffolds help regenerate wounds and hair by activating the immune system.

Immune checkpoint inhibitors used in cancer therapy can cause hair loss, and understanding this can help manage the side effect.

γδ T cells can prevent and treat alopecia areata, offering a new therapy option.

Some patients on immune therapy for melanoma may develop scarring hair loss, but cancer treatment remains effective.

Collagen VII helps skin heal and stay strong, sirolimus may lower skin cancer risk in kidney transplant patients, high-molecular-mass hyaluronan helps naked mole rats resist cancer, dermal γδ T cells aid in hair growth in rodents, and overexpression of IL-33 in mouse skin causes itchiness, offering a model for studying allergic inflammation treatments.

The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.

Damaging mutations in NFKB2 cause a severe and distinct form of primary immunodeficiency with early-onset and often ACTH-deficiency.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

Exosomes from certain cells can improve hair regrowth by changing the immune response.

Artificial skin grafts face immune rejection, but stem cells may improve future designs.

Feathers become harder as they develop due to a change in keratin type.

Melanocytes might be targeted by the immune system in people with alopecia areata, but more research is needed.

TNF-alpha inhibitors can cause various immune-related skin issues.

Different γδ T cell types have unique roles in causing alopecia areata.

Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.